Literature DB >> 6141606

A pharmacokinetic/pharmacodynamic/receptor binding model to predict the onset and duration of pharmacological activity of the benzodiazepines.

M L Jack, W A Colburn, N M Spirt, G Bautz, M Zanko, W D Horst, R A O'Brien.   

Abstract

Ex vivo receptor binding as a function of time was determined in Charles River rats. The pharmacokinetic and protein binding parameters in man as well as the ex vivo receptor binding parameters in rat brain for three benzodiazepine induction agents, diazepam, lorazepam and midazolam, were used to develop and test a pharmacokinetic/pharmacodynamic/receptor binding model. The model was subsequently used to predict changes in receptor binding and pharmacodynamics as a function of changes in pharmacokinetics. The model was found to be a good predictor of the relative onset and duration of the sedative and amnesic properties in normal subjects as well as in the presence of certain patho-physiological conditions and certain drug interactions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6141606     DOI: 10.1016/0278-5846(83)90036-2

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  12 in total

1.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

Review 2.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

4.  Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics.

Authors:  C E Lau; F Ma; Y Wang; C Smith
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

5.  The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma.

Authors:  H Friedman; D R Abernethy; D J Greenblatt; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  In vivo cerebral pharmacokinetics and pharmacodynamics of diazepam and midazolam after short intravenous infusion administration in sheep.

Authors:  R N Upton; G L Ludbrook; C Grant; A Martinez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

7.  Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam.

Authors:  E H Ellinwood; D G Heatherly; A M Nikaido; T D Bjornsson; C Kilts
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Dexmedetomidine synergism with midazolam in the elevated plus-maze test in rats.

Authors:  M Salonen; E S Onaivi; M Maze
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Diazepam: prediction of pharmacodynamics from pharmacokinetics.

Authors:  E H Ellinwood; A Nikaido; D Heatherly
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms.

Authors:  E H Ellinwood; A M Nikaido; D G Heatherly; T D Bjornsson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.